Overview

Dr. Gregory Priebe’s research focus is on the prevention of hospital-acquired infections, which he pursues through leadership in patient safety and quality efforts, through clinical research on ventilator-associated pneumonia (VAP) and ventilator-associated events (VAE), and through basic research on bacterial genomics and vaccines. Dr. Priebe’s basic research lab studies the Gram-negative bacteria Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and members of the Burkholderia cepacia complex, all with the long-term goal of developing vaccines and new antimicrobials. Techniques used in the Priebe lab span multiple fields, including microbiology, molecular biology, bacterial genomics, cellular and molecular immunology, and animal models of infection.

In parallel with his bench research program, Dr. Priebe runs the Critical Care Infection Prevention Program (CCIPP) at Boston Children’s Hospital. The CCIPP consists of the Nosocomial Infection Oversight Committee (NIOC), which oversees healthcare-associated infection surveillance and infection prevention practices for the hospital’s 4 ICUs, and the Translational Research for Infection Prevention in Pediatric Anesthesia and Critical Care (TRIPPACC) Program, which is a multidisciplinary research group of investigators in pediatric critical care medicine, bacterial pathogenesis, infectio

Background

Dr. Gregory Priebe earned his medical degree from Harvard Medical School and then went on to complete residency and chief residency in Pediatrics at Boston Children’s Hospital followed by fellowships in Pediatric Infectious Diseases and Pediatric Critical Care Medicine, also at Boston Children’s Hospital. He is board certified in Pediatric Infectious Diseases and Pediatric Critical Care Medicine.

Dr. Priebe is the Associate Program Director for the Fellowship in Pediatric Critical Care Medicine, where he serves as the Director of Fellow Research, and he is also the physician site leader at Boston Children’s for the national Solutions for Patient Safety network.

Key Publications

  1. LiebermanTD, MichelJB, Aingaran M, Potter-Bynoe G, Roux D, Davis MR, Skurnik D, Leiby N, LiPuma JJ, Goldberg JB, McAdam AJ, Priebe GP, Kishony R. Parallel bacterial evolution within multiple patients ties novel genes to pathogenesis.  Nat Genetics 2011; 43(12):1275-80(PMCID3245322).
  2. Skurnik D, Davis Jr. MR, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litràn T, Cassidy SB, Hermos CR, Martin TR, ThakkallapalliEL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, LiPuma JJ, Pier GB, Goldberg JB, Priebe GP. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205(11):1709-18. Epub 2012 Mar 23 (PMCID3415848).
  3. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.  Am J Respir Crit Care Med 2012;186(5):420-7. Epub 2012 Jun 21
  4. Kamei A, Wu W, Traficante DC, Koh AY, Van RooijenN, Pier GB, Priebe GP.Collaboration between macrophages and vaccine-induced CD4 T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis 2012, Epub 2012 Nov 21.
  5. Hong H, Morrow DF, Sandora TJ, Priebe GP.  Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity.  Am J Infect Control 2012, in press.

Researcher Services

Researcher Areas

  • Bacterial Infection
  • Cystic Fibrosis
  • Vaccines
  • Ventilator-associated events
  • Ventilator-associated pneumonia

Research Departments

Research Divisions

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, Hinkle M, Lesho E, McGann P, McAdam AJ, Sandora TJ, Kishony R, Priebe GP. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019 Nov; 25(11):1728-1732. View abstract
  2. Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, Biggs CM, Gorman M, Lehmann L, Lo MS, Nigrovic PA, Platt CD, Priebe GP, Rowe J, Sundel RP, Surana NK, Weinacht KG, Mann A, Yuen JC, Meleedy-Rey P, Starmer A, Banerjee T, Dedeoglu F, Degar BA, Hazen MM, Henderson LA. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View abstract
  3. Bernardy EE, Petit RA, Moller AG, Blumenthal JA, McAdam AJ, Priebe GP, Chande AT, Rishishwar L, Jordan IK, Read TD, Goldberg JB. Whole-Genome Sequences of Staphylococcus aureus Isolates from Cystic Fibrosis Lung Infections. Microbiol Resour Announc. 2019 Jan; 8(3). View abstract
  4. Merakou C, Schaefers MM, Priebe GP. Progress Toward the Elusive Pseudomonas aeruginosa Vaccine. Surg Infect (Larchmt). 2018 Nov/Dec; 19(8):757-768. View abstract
  5. Karandikar MV, Coffin SE, Priebe GP, Sandora TJ, Logan LK, Larsen GY, Toltzis P, Gray JE, Klompas M, Sammons JS, Harper MB, Horan K, Lakoma M, Cocoros NM, Lee GM. Variability in antimicrobial use in pediatric ventilator-associated events. Infect Control Hosp Epidemiol. 2019 01; 40(1):32-39. View abstract
  6. Schaefers MM, Duan B, Mizrahi B, Lu R, Reznor G, Kohane DS, Priebe GP. PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. Vaccine. 2018 11 12; 36(46):6926-6932. View abstract
  7. Liu C, Pan X, Xia B, Chen F, Jin Y, Bai F, Priebe G, Cheng Z, Jin S, Wu W. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa Strains Based on Expression Profiling of Outer Membrane Proteins During Infection. Front Immunol. 2018; 9:1737. View abstract
  8. Roux D, Schaefers M, Clark BS, Weatherholt M, Renaud D, Scott D, LiPuma JJ, Priebe G, Gerard C, Yoder-Himes DR. A putative lateral flagella of the cystic fibrosis pathogen Burkholderia dolosa regulates swimming motility and host cytokine production. PLoS One. 2018; 13(1):e0189810. View abstract
  9. Barsky EE, Pereira LM, Sullivan KJ, Wong A, McAdam AJ, Sawicki GS, Priebe GP, Goobie SM. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):e25-e31. View abstract
  10. Cocoros NM, Priebe G, Gray JE, Toltzis P, Larsen GY, Logan LK, Coffin S, Sammons JS, Deakins K, Horan K, Lakoma M, Young J, Burton M, Klompas M, Lee GM. Factors Associated With Pediatric Ventilator-Associated Conditions in Six U.S. Hospitals: A Nested Case-Control Study. Pediatr Crit Care Med. 2017 Nov; 18(11):e536-e545. View abstract
  11. Barsky EE, Williams KA, Priebe GP, Sawicki GS. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017 10; 52(10):1276-1282. View abstract
  12. Roux D, Weatherholt M, Clark B, Gadjeva M, Renaud D, Scott D, Skurnik D, Priebe GP, Pier G, Gerard C, Yoder-Himes DR. Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa. Infect Immun. 2017 06; 85(6). View abstract
  13. Koutsogiannaki S, Schaefers MM, Okuno T, Ohba M, Yokomizo T, Priebe GP, DiNardo JA, Sulpicio SG, Yuki K. From the Cover: Prolonged Exposure to Volatile Anesthetic Isoflurane Worsens the Outcome of Polymicrobial Abdominal Sepsis. Toxicol Sci. 2017 04 01; 156(2):402-411. View abstract
  14. Chung H, Lieberman TD, Vargas SO, Flett KB, McAdam AJ, Priebe GP, Kishony R. Global and local selection acting on the pathogen Stenotrophomonas maltophilia in the human lung. Nat Commun. 2017 01 19; 8:14078. View abstract
  15. Schaefers MM, Liao TL, Boisvert NM, Roux D, Yoder-Himes D, Priebe GP. An Oxygen-Sensing Two-Component System in the Burkholderia cepacia Complex Regulates Biofilm, Intracellular Invasion, and Pathogenicity. PLoS Pathog. 2017 01; 13(1):e1006116. View abstract
  16. Cocoros NM, Priebe GP, Logan LK, Coffin S, Larsen G, Toltzis P, Sandora TJ, Harper M, Sammons JS, Gray JE, Goldmann D, Horan K, Burton M, Checchia PA, Lakoma M, Sims S, Klompas M, Lee GM. A Pediatric Approach to Ventilator-Associated Events Surveillance. Infect Control Hosp Epidemiol. 2017 03; 38(3):327-333. View abstract
  17. Schlosser K, Smallwood C, Arnold J, Lee G, Priebe G, Walsh B, Santillana M. 1015: IDENTIFICATION OF PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS USING CONTINUOUS VENTILATOR DATA. Crit Care Med. 2016 Dec; 44(12 Suppl 1):330. View abstract
  18. Cronin J, Kinlay J, Lee G, Priebe G. 1214: PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS ARE RARELY ASSOCIATED WITH INFECTION. Crit Care Med. 2016 Dec; 44(12 Suppl 1):379. View abstract
  19. Zhao G, Zaidi TS, Bozkurt-Guzel C, Zaidi TH, Lederer JA, Priebe GP, Pier GB. Efficacy of Antibody to PNAG Against Keratitis Caused by Fungal Pathogens. Invest Ophthalmol Vis Sci. 2016 12 01; 57(15):6797-6804. View abstract
  20. Albert BD, Zurakowski D, Bechard LJ, Priebe GP, Duggan CP, Heyland DK, Mehta NM. Enteral Nutrition and Acid-Suppressive Therapy in the PICU: Impact on the Risk of Ventilator-Associated Pneumonia. Pediatr Crit Care Med. 2016 10; 17(10):924-929. View abstract
  21. Cocoros NM, Kleinman K, Priebe GP, Gray JE, Logan LK, Larsen G, Sammons J, Toltzis P, Miroshnik I, Horan K, Burton M, Sims S, Harper M, Coffin S, Sandora TJ, Hocevar SN, Checchia PA, Klompas M, Lee GM. Ventilator-Associated Events in Neonates and Children--A New Paradigm. Crit Care Med. 2016 Jan; 44(1):14-22. View abstract
  22. Gauguet S, D'Ortona S, Ahnger-Pier K, Duan B, Surana NK, Lu R, Cywes-Bentley C, Gadjeva M, Shan Q, Priebe GP, Pier GB. Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia. Infect Immun. 2015 Oct; 83(10):4003-14. View abstract
  23. Flett KB, Ozonoff A, Graham DA, Sandora TJ, Priebe GP. Impact of Mandatory Public Reporting of Central Line-Associated Bloodstream Infections on Blood Culture and Antibiotic Utilization in Pediatric and Neonatal Intensive Care Units. Infect Control Hosp Epidemiol. 2015 Aug; 36(8):878-85. View abstract
  24. Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, Magill SS, Maragakis LL, Priebe GP, Speck K, Yokoe DS, Berenholtz SM. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Sep; 35 Suppl 2:S133-54. View abstract
  25. Zaidi T, Zaidi T, Cywes-Bentley C, Lu R, Priebe GP, Pier GB. Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye. Infect Immun. 2014 Aug; 82(8):3483-91. View abstract
  26. Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr; 13(4):507-19. View abstract
  27. Lieberman TD, Flett KB, Yelin I, Martin TR, McAdam AJ, Priebe GP, Kishony R. Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat Genet. 2014 Jan; 46(1):82-7. View abstract
  28. Djonovic S, Urbach JM, Drenkard E, Bush J, Feinbaum R, Ausubel JL, Traficante D, Risech M, Kocks C, Fischbach MA, Priebe GP, Ausubel FM. Trehalose biosynthesis promotes Pseudomonas aeruginosa pathogenicity in plants. PLoS Pathog. 2013 Mar; 9(3):e1003217. View abstract
  29. Hong H, Morrow DF, Sandora TJ, Priebe GP. Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity. Am J Infect Control. 2013 Aug; 41(8):e77-9. View abstract
  30. Kamei A, Wu W, Traficante DC, Koh AY, Van Rooijen N, Pier GB, Priebe GP. Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis. 2013 Jan 01; 207(1):39-49. View abstract
  31. Tamang DL, Pirzai W, Priebe GP, Traficante DC, Pier GB, Falck JR, Morisseau C, Hammock BD, McCormick BA, Gronert K, Hurley BP. Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol. 2012 Nov 15; 189(10):4960-9. View abstract
  32. Zaidi TS, Zaidi T, Pier GB, Priebe GP. Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun. 2012 Oct; 80(10):3706-12. View abstract
  33. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012 Sep 01; 186(5):420-7. View abstract
  34. Skurnik D, Davis MR, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litràn T, Cassidy SK, Hermos CR, Martin TR, Thakkallapalli EL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, Lipuma JJ, Pier GB, Goldberg JB, Priebe GP. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis. 2012 Jun; 205(11):1709-18. View abstract
  35. Lieberman TD, Michel JB, Aingaran M, Potter-Bynoe G, Roux D, Davis MR, Skurnik D, Leiby N, LiPuma JJ, Goldberg JB, McAdam AJ, Priebe GP, Kishony R. Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet. 2011 Nov 13; 43(12):1275-80. View abstract
  36. Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun. 2011 Mar; 79(3):1289-99. View abstract
  37. Kamei A, Koh AY, Gadjeva M, Priebe GP, Lory S, Pier GB. Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model. J Infect Dis. 2010 Jan 01; 201(1):71-80. View abstract
  38. Gadjeva M, Paradis-Bleau C, Priebe GP, Fichorova R, Pier GB. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J Immunol. 2010 Jan 01; 184(1):296-302. View abstract
  39. Koh AY, Priebe GP, Ray C, Van Rooijen N, Pier GB. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun. 2009 Dec; 77(12):5300-10. View abstract
  40. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol. 2008 Oct 01; 181(7):4965-75. View abstract
  41. Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med. 2007 Aug 06; 204(8):1901-9. View abstract
  42. Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006 Feb; 74(2):975-83. View abstract
  43. Priebe GP. Sepsis in the immunocompromised child: the least studied with the most to gain. Pediatr Crit Care Med. 2005 May; 6(3 Suppl):S78-9. View abstract
  44. Koh AY, Priebe GP, Pier GB. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun. 2005 Apr; 73(4):2262-72. View abstract
  45. Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 01; 173(9):5671-8. View abstract
  46. Priebe GP, Dean CR, Zaidi T, Meluleni GJ, Coleman FT, Coutinho YS, Noto MJ, Urban TA, Pier GB, Goldberg JB. The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun. 2004 Jul; 72(7):4224-32. View abstract
  47. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun. 2003 Mar; 71(3):1453-61. View abstract
  48. Priebe GP, Pier GB. Vaccines for Pseudomonas aeruginosa. In: Ellis RW, Brodeur BR, editors. New bacterial vaccines. 2003; 261-283. View abstract
  49. Priebe GP, Brinig MM, Hatano K, Grout M, Coleman FT, Pier GB, Goldberg JB. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun. 2002 Mar; 70(3):1507-17. View abstract
  50. Priebe GP, Arnold JH. High-frequency oscillatory ventilation in pediatric patients. Respir Care Clin N Am. 2001 Dec; 7(4):633-45. View abstract
  51. Heininger A, Ulrich M, Priebe G, Unertl K, Müller-Schauenburg A, Botzenhart K, Döring G. The effect of human serum DNAases on the ability to detect antibiotic-killed Escherichia coli in blood by PCR. J Med Microbiol. 2001 Mar; 50(3):243-8. View abstract
  52. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun. 2000 Jul; 68(7):3998-4004. View abstract
  53. Harris EW, D'Amico DJ, Bhisitkul R, Priebe GP, Petersen R. Bacterial subretinal abscess: a case report and review of the literature. Am J Ophthalmol. 2000 Jun; 129(6):778-85. View abstract
  54. Headrick LA, Richardson A, Priebe GP. Continuous improvement learning for residents. Pediatrics. 1998 Apr; 101(4 Pt 2):768-73; discussion 773-4. View abstract